Stock Events

Stock Events

vTv Therapeutics

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5VT0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen has a strong portfolio in neurodegenerative diseases, including Alzheimer's, making it a direct competitor to vTv Therapeutics.

Axsome Therapeutics

Axsome Therapeutics works on central nervous system disorders, including Alzheimer's disease, competing in the same space as vTv Therapeutics.

AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, which could overlap with vTv Therapeutics' work on conditions like psoriasis.

Acadia Pharmaceuticals

ACADIA Pharmaceuticals focuses on central nervous system disorders, posing competition to vTv Therapeutics' Alzheimer's disease treatments.

Alkermes works on central nervous system diseases, including treatments for schizophrenia and bipolar I disorder, areas that could compete with vTv Therapeutics' focus.

Amgen's broad focus on innovative therapeutics includes work on neurodegenerative diseases, making it a competitor in the Alzheimer's space.

AbbVie has a diverse portfolio that includes neuroscience, directly competing with vTv Therapeutics in the Alzheimer's and cognitive impairment market.

Eli Lilly has a strong presence in Alzheimer's disease research and treatment, directly competing with vTv Therapeutics.

Pfizer has a wide range of therapeutic areas, including Alzheimer's disease research, making it a competitor to vTv Therapeutics.

About

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Show more...

CEO

Mr. Paul J. Sekhri

Employees

26

Country

Germany

ISIN

US9183852048

Listings

0 Comments

Share your thoughts

FAQ

What is vTv Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange vTv Therapeutics stocks are traded under the ticker 5VT0.MU.

How many employees does vTv Therapeutics have?▼

As of April 11, 2026, the company has 26 employees.

In which sector is vTv Therapeutics located?▼

vTv Therapeutics operates in the Other sector.

When did vTv Therapeutics complete a stock split?▼

vTv Therapeutics has not had any recent stock splits.

Where is vTv Therapeutics headquartered?▼

vTv Therapeutics is headquartered in High Point, Germany.